Aroa Biosurgery Limited (AROAF)

Market Cap	86.04M
Revenue (ttm)	48.59M
Net Income (ttm)	-4.85M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3,088
Open	0.2439
Previous Close	0.2439
Day's Range	0.2439 - 0.2439
52-Week Range	0.2439 - 0.4000
Beta	n/a
RSI	n/a
Earnings Date	Apr 29, 2025

About Aroa Biosurgery

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that de...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Country: New Zealand
• Stock Exchange: OTCMKTS
• Ticker Symbol: AROAF

Financial Performance

In 2023, Aroa Biosurgery's revenue was 69.07 million, an increase of 9.01% compared to the previous year's 63.36 million. Losses were -10.63 million, 2583.8% more than in 2022.

Financial numbers in NZD